Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (CMPX) reported a third-quarter net loss of $27.2 million while continuing preparations for a tovecimig marketing application.
The loss was $0.15 per share, versus $0.08 a year earlier. Cash and marketable securities totaled $163 million at September 30, 2026; Compass expects funding to last into 2028 under current operating plans. The FDA recommended another study demonstrating a survival benefit before a biologics license application; Compass believes another trial is unwarranted and plans further FDA engagement.
COMPANION-002 met its response-rate and progression-free survival endpoints, but neither the unadjusted nor exploratory crossover-adjusted overall survival analysis showed statistical significance. Compass expects CTX-8371 and CTX-10726 study updates later in 2026 and initial CTX-471 Phase 2 data in the second half of 2027.
Compass Therapeutics (CMPX) will present preclinical findings on its cancer antibody CTX-10726 at the SITC annual meeting on November 7, 2026. CTX-10726 targets PD-1 and VEGF-A. Studies showed that it removed PD-1 receptors from T-cell surfaces only in the presence of VEGF-A.
Adding VEGF-A increased potency approximately ten-fold in a human immune-cell assay. A mouse version of CTX-10726 combined with CTX-471 inhibited tumor growth more than either agent alone in checkpoint inhibitor-resistant mouse models. An ongoing Phase 1 dose-escalation study is enrolling patients with advanced solid tumors after checkpoint treatment and failure of standard therapies.
Compass Therapeutics (CMPX) will participate in the Guggenheim healthcare investor conference on November 9, 2026, and Stifel’s conference on November 11, 2026.
The Guggenheim 3rd Annual Healthcare Innovation Conference presentation is scheduled for 1:30 PM ET; the Stifel 2026 Healthcare Conference presentation is at 11:20 AM ET. Presentations will be archived on Compass’ Events page. Management will be available for one-on-one meetings at both events; interested investors should contact their respective representatives.
Compass Therapeutics (Nasdaq: CMPX) announced publication and ESMO presentation of Phase 2/3 COMPANION-002 results for tovecimig in previously treated advanced biliary tract cancer.
The 168-patient trial compared tovecimig plus paclitaxel with paclitaxel alone. It met its primary endpoint of objective response rate, measuring tumor responses: 18.0% versus 5.3%. Median progression-free survival, time without disease worsening or death, was 4.7 versus 2.6 months, meeting the key secondary endpoint. Median response duration was 4.9 months; disease control was 62.2% versus 36.8%.
Overall survival did not differ significantly. A post hoc exploratory analysis adjusting for treatment crossover also lacked statistical significance (hazard ratio 0.85; p=0.53). Grade 3 or higher treatment-emergent adverse events occurred in 93.5% versus 64.2%; events leading to death occurred in 5.6% versus 1.9%, respectively.
Compass Therapeutics (CMPX) granted a new employee stock options covering 200,000 common shares as an inducement to employment under its 2025 Inducement Plan.
The exercise price is $0.86 per share, matching the October 13, 2026 closing share price. The options have a 10-year term and vest over four years: 25% on the grant’s first anniversary and the remaining 75% in 36 substantially equal monthly installments, subject to continued service. The grant complies with Nasdaq Listing Rule 5635(c)(4), sits outside the 2020 Stock Option and Incentive Plan, and is subject to the 2025 Inducement Plan and applicable award agreement.
Compass Therapeutics (CMPX) reported that the U.S. FDA has recommended conducting an additional trial showing an overall survival benefit before submitting a Biologics License Application (BLA) for tovecimig in previously treated, advanced biliary tract cancer (BTC).
The company does not believe a new trial is warranted before BLA submission, citing the Phase 2/3 COMPANION-002 study, in which tovecimig plus paclitaxel achieved a statistically significant improvement in objective response rate (18.0% vs. 5.3%; p=0.0228) and progression-free survival (median 4.7 vs. 2.6 months; hazard ratio 0.44; p<0.0001) versus paclitaxel alone. Overall survival did not reach statistical significance due to high crossover and prolonged survival in crossover patients. Compass plans further engagement with the FDA while preparing a BLA and states that the safety profile was generally consistent with prior tovecimig studies.
Compass Therapeutics (Nasdaq: CMPX) reported 2026 Q2 results and a corporate update, highlighting progress across its oncology pipeline and liquidity of $180 million in cash and marketable securities as of June 30, 2026, which the company expects will fund operations into 2028.
For biliary tract cancer, final Phase 2/3 data for tovecimig showed an ORR of 18.0% (20/111) in the combination arm versus 5.3% for paclitaxel alone, with a p-value of 0.0228; FDA feedback on these data is expected in Q3 ahead of a potential BLA filing later in 2026, and the dataset will be presented orally at ESMO. CTX-8371 Phase 1 cohort expansions in multiple tumors are enrolling, with additional data expected in Q4 2026, CTX-10726 first-in-human dosing has begun with initial data also expected in Q4, and a Phase 2 study of CTX-471 in NCAM(CD56)-positive tumors is planned to start in Q3.
Net loss was $25.2 million for Q2 2026 versus $19.9 million a year earlier, driven by higher R&D and pre-commercialization G&A expenses.
Compass Therapeutics (Nasdaq: CMPX) reported that its abstract, “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer,” has been accepted for an oral Proffered Paper presentation at the ESMO Congress 2026 in Madrid, Spain.
The presentation will cover results from the randomized, controlled Phase 2/3 COMPANION-002 trial evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel in patients with advanced biliary tract cancer. According to Compass Therapeutics, Dr. Nilofer Azad of Johns Hopkins University will present on Saturday, October 24, 2026, during a session scheduled from 10:15am–11:45am CET.
Compass Therapeutics (Nasdaq:CMPX) will participate in two June 2026 investor conferences focused on healthcare.
Management will present at the Jefferies Global Healthcare Conference on June 4 at 8:45 AM ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 AM ET, with webcasts and replays available.
Compass Therapeutics (Nasdaq:CMPX) will present Phase 1 data for CTX-8371, a dual PD-1×PD-L1 bispecific antibody, in advanced malignancies post-checkpoint inhibition at the 2026 ASCO Annual Meeting.
Among 15 evaluable patients, three responses were reported, with a 33% ORR at higher doses and no dose-limiting toxicities.